Systematic validation of predicted microRNAs for cyclin D1 by Jiang, Qiong et al.
BioMed  Central
Page 1 of 13
(page number not for citation purposes)
BMC Cancer
Open Access Research article
Systematic validation of predicted microRNAs for cyclin D1
Qiong Jiang1,2, Ming-Guang Feng*2 and Yin-Yuan Mo*1
Address: 1Department of Medical Microbiology, Immunology and Cell Biology, Southern Illinois University School of Medicine, Springfield, IL, 
USA and 2Institute of Microbiology, College of Life Sciences, Zhejiang University, Hangzhou, PR China
Email: Qiong Jiang - qjiang@siumed.edu; Ming-Guang Feng* - mgfeng@zju.edu.cn; Yin-Yuan Mo* - ymo@siumed.edu
* Corresponding authors    
Abstract
Background:  MicroRNAs are the endogenous small non-coding RNA molecules capable of
silencing protein coding genes at the posttranscriptional level. Based on computer-aided
predictions, a single microRNA could have over a hundred of targets. On the other hand, a single
protein-coding gene could be targeted by many potential microRNAs. However, only a relatively
small number of these predicted microRNA/mRNA interactions are experimentally validated, and
no systematic validation has been carried out using a reporter system.
Methods: In this study, we used luciferease reporter assays to validate microRNAs that can silence
cyclin D1 (CCND1) because CCND1 is a well known proto-oncogene implicated in a variety of
types of cancers. We chose miRanda http://www.microRNA.org as a primary prediction method.
We then cloned 51 of 58 predicted microRNA precursors into pCDH-CMV-MCS-EF1-copGFP and
tested for their effect on the luciferase reporter carrying the 3'-untranslated region (UTR) of
CCND1 gene.
Results: Real-time PCR revealed the 45 of 51 cloned microRNA precursors expressed a relatively
high level of the exogenous microRNAs which were used in our validation experiments. By an
arbitrary cutoff of 35% reduction, we identified 7 microRNAs that were able to suppress Luc-
CCND1-UTR activity. Among them, 4 of them were previously validated targets and the rest 3
microRNAs were validated to be positive in this study. Of interest, we found that miR-503 not only
suppressed the luciferase activity, but also suppressed the endogenous CCND1 both at protein and
mRNA levels. Furthermore, we showed that miR-503 was able to reduce S phase cell populations
and caused cell growth inhibition, suggesting that miR-503 may be a putative tumor suppressor.
Conclusion:  This study provides a more comprehensive picture of microRNA/CCND1
interactions and it further demonstrates the importance of experimental target validation.
Background
Accumulating evidence indicates that microRNAs could
play a fundamental role in regulation of diverse cellular
pathways including differentiation, proliferation and
apoptosis [1,2]. Thus, deregulation of microRNAs affects
normal cell growth and development, leading to a variety
of disorders including human malignancies, which have
been demonstrated in both in vitro and in vivo systems
[1,3-6]. Importantly, tumor cells often express a unique
set of microRNAs (or microRNA signature). For example,
the overall microRNA expression profile of normal tissues
is distinct from that of tumor tissues [7] and moreover,
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microRNA signatures are able to accurately identify cancer
tissue origin [8]. MicroRNAs can function as tumor sup-
pressors or oncogenes depending on whether they specif-
ically target oncogenes or tumor suppressor genes [9-11].
For instance, tumor suppressive microRNAs such as let-7,
miR-15 and miR-16 are downregulated or deleted in lung
cancer and leukemia [11-13]. In contrast, oncogenic
microRNAs, such as miR-21 and miR-155, are overex-
pressed in tumors or tumor cell lines [7,14,15].
Since microRNAs are capable of silencing gene expression
by binding to the 3'-untranslated region (3'-UTR) with
partial sequence homology, a single microRNA usually
has multiple targets [16]. Thus, microRNAs could regulate
a large fraction of protein-coding genes. As high as 30% of
all genes could be microRNA targets [17,18]. In essence,
microRNAs can be considered to be modulators of gene
regulators and they can cooperate with transcription fac-
tors. Together, microRNAs and transcription factors deter-
mine gene expression patterns in the cell [19].
Despite the tremendous progress made in the past several
years in identification of microRNAs and their role in
diverse cellular functions, the mechanism of microRNA-
mediated tumorigenesis is still poorly understood pre-
sumably because we do not have a clear picture as to how
microRNAs silence their target genes. Given the nature of
microRNA targeting, a single protein coding gene
(mRNA) can be targeted by multiple microRNAs. For
example, CCND1 can be potentially targeted by as many
as several dozens of microRNAs depending on which pre-
diction method is used. However, it is not clear how many
microRNAs actually can target CCND1. Since CCND1 is a
key gene controlling cell cycle and it is frequently overex-
pressed in cancer cells, contributing to cell proliferation
and migration [20], we thought that CCND1 would be an
idea gene for microRNA target validation because a few
microRNAs have been previously validated, such as miR-
17/20 [21], miR-16 family [22,23], and let-7 [24]; and a
relatively large number of microRNAs are predicted to tar-
get CCND1.
Therefore, we attempted to validate these predicted micro-
RNAs in a biological reporter system. We found 7 micro-
RNAs are positive to CCND1. In addition to previously
validated microRNAs, we found that miR-503 can cause
cell cycle arrest and growth inhibition through in part
silencing CCND1. To our knowledge, this is the first sys-
tematic target validation effort using the biological
reporter system and thus, it is expected to provide more
comprehensive view of how microRNAs regulate this
important gene.
Methods
Cell Culture and Reagents
Human head and neck carcinoma cell line UMSCC10B
has been described previously [25] and was grown in
DMEM (Cambrex, Walkersville, MD) supplemented with
10% fetal bovine serum (Sigma-Aldrich, St. Louis, Mo), 2
mM-glutamine, 100 units of penicillin/ml and 100 μg of
streptomycin/ml (Cambrex). The cultivation of immortal-
ized kidney epithelial cells 293T (ATCC) has been previ-
ously described [26]. All cells were incubated at 37°C in a
humidified chamber supplemented with 5% CO2.
Scrambled LNA (locked nucleic acid) oligonucleotide and
anti-miR-503 LNA oligonucleotide were purchased from
IDT (Coralville, IA). Primary anti-CCND1 antibody (Epi-
tomics, Burlingame, CA) and anti-β-actin antibody
(Sigma. St. Louis, Mo) were used in western blot. Second-
ary antibodies conjugated with IRDye 800CW were pur-
chased from LI-COR Biosciences (Lincoln, NE). PCR
primers were purchased from Sigma-Genosys (Woodland,
TX) or IDT.
Plasmid constructs
To construct pre-microRNA expression vectors, we first
amplified ~0.5 kb DNA fragment covering a pre-micro-
RNA, using genomic DNA from a healthy blood donor as
a template. PCR reactions were performed using the high
fidelity Phusion enzyme (New England Biolabs Ipswich,
MA) and corresponding specific primers as listed in Table
1. The amplified fragment was first cloned into a PCR
cloning vector (pCR8) and subsequently cloned a lentivi-
ral vector (pCDH-CMV-MCS-EF1-copGFP from System
Biosciences, Mountain View, CA) at EcoR1 and Not1 sites.
Where there was an internal EcoR1 or Not1 site, partial
digestions were performed to obtain the DNA fragment
carrying the pre-microRNA. Expression of the mature
microRNAs was verified by QuantiMir kit (System Bio-
sciences) or TaqMan real-time PCR kit (Applied Biosys-
tems) [27,28].
The luciferase-UTR reporter plasmids (Luc-CCND1-3'-
UTR-1 and Luc-CCND1-3'-UTR-2) were constructed by
introducing the CCND1 3'-UTR carrying putative micro-
RNA binding sites into pGL3 control vector (Promega,
Madison, WI). Thus, we amplified the CCND1 3'-UTR
sequence from MCF10A cDNA by PCR using the primers
as follows.
CCND1-UTR-5.2 (sense) 5'-GGGCGCCAGGCAGGCG-
GGCGC (1–21)CCND1-UTR-Not1-3.2 (antisense) 5'-
GCGGCCGCTGGTTTTAGAATATGAAGAAG (981–1002)
for Luc-CCND1-3'-UTR-1.
CCND1-UTR-5.3 (sense) 5'-ACGTCCAGGTTCAAC-
CCACAG (944–965)CCND1-UTR-Not1-3.4 (antisense)BMC Cancer 2009, 9:194 http://www.biomedcentral.com/1471-2407/9/194
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Table 1: Primers used to clone microRNA precursors in this study
MicroRNA 5' primer 3' primer
miR-19a GCATCTACTGCAGTGAAGGC GCGGCCGCAGTTTGATTGGGCGACAGG
miR-491 AGATGGCTTTCTGGGTAGCC GCGGCCGCTAACAGTAACACGTATGGGC
miR-296 CCTCCTTGGAGCTGAGATGG GCGGCCGCGTGGGAGGTAGGTAAAACTC
miR-532 CATCTGTTCTCGTATGTGTG GCGGCCGCACGTAAGAGAGGGTTTACC
miR-188 CTTCCCTCTCCAGTGCATAG GCGGCCGCTCCTGCAGGATCCATGTAAG
miR-579 CAGTGACAGAGTTGTGTAAC GCGGCCGCGTGGAAACAAGTTGCATGTC
miR-501 AGACCCTCAAGTGTGATCTG GCGGCCGCAGTATATGCAGGGGCAATG
miR-548c TCAGGGTTTCACCATGTTGG GCGGCCGCACAGAGCAAGACTCCATCTC
miR-219-1 CGTTTACTCTAGAGTCCTCG GCGGCCGCACAGAGGGCTCGTGAAAAGG
miR-340 TGGCTACCTGTTCAGCTTTC GCGGCCGCAGCAGTTTACCAGAATACCG
miR-519b CTGGACACAAAACTCAGGAG GCGGCCGCGTCTGGGTCACAGAGCAAG
miR-155 TGCCTAAAGGTAACAATGTC GCGGCCGCGGTTGAACATCCCAGTGAC
miR-519e GGTATGTGTGGTAGGCTTTG GCGGCCGCAACTAGCCTAAGAGGTCTAG
miR-515-1 TACATGCCACCACAGGCGGC GCGGCCGCCTGGGCCACAGAGAGAGAC
miR-139 GATCGTGCAGGCAACTCTTG GCGGCCGCTGGATAACAAGGCAGTATGG
miR-494 TTCCCGGGCAACCTCTTTTC GCGGCCGCTCCTTCAACCACAGAAGCAC
miR-203 CGTCTAAGGCGTCCGGTACG GCGGCCGCTTCCCACAGCACAGCCCGGC
miR-142 GATGGGGTGGAGCCTTTAGG GCGGCCGCAACCAGGAAGGGCAGGAAAG
miR-450-1 TGATTATCTCTGAGTTGTGG GCGGCCGCAAAATGATCCCAATACAC
miR-193a AGTTTCTCGGCGCATAACTC GCGGCCGCTATTTCTCCAGCGAAGTG
miR-193b GTTGTCCGGGAAGCTTTTAG GCGGCCGCCCTCGAAGGGACCTTTTAG
miR-487b TGGTCTGGGTCCCTGCTTCC GCGGCCGCAGTCATAAAACCACCACCAC
miR-487a CAGTCTCATGAGGGAGTGCC GCGGCCGCTCTCACTGGTCAACTTCCC
miR-301 AGGGCTTGTTTTACATGGCG GCGGCCGCCAGACGTGTTTCATAATGC
miR-130a CTGCTTTAGTGGGTCCTGTC GCGGCCGCTAACGGAGGCAGTGTCTATC
miR-130b GTCAAAGCATCTGGGACCAG GCGGCCGCACCTGATCCTCTGATGGAG
miR-148a CTTTGCTGTGACATTGCGAC GCGGCCGCTTTGGGGGGATTTTGTTCCCBMC Cancer 2009, 9:194 http://www.biomedcentral.com/1471-2407/9/194
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miR-503 CTCGTGGGGAAGGTAGAAGG GCGGCCGCAAGATAGGTTTTCTTCGTTG
miR-152 AGCAGCCAACTCAGAACTCG GCGGCCGCAAGGTCCACAGCTGGTTCTG
miR-95 CCTCCTGAGGAATCCAGGCG GCGGCCGCGATCGGGCCCTTGCGAAGCC
miR-550 GAGCCTTCTAACCACAACCC GCGGCCGCATAAAGCAGTTCCTACACTC
miR-545 TCATGCCAGTGTCTAGTTCC GCGGCCGCCACCAAGAAAGCAAGTGTC
miR-424 ACCCACTACGTTGTTCCAAG GCGGCCGCAGAGCACCGATCGCTCACTG
miR-15a AAAGGTGTACTGCAAGGAAC GCGGCCGCACTGCTGACATTGCTATC
miR-16 GCTAGGTTGGATGAATCCTAC GCGGCCGCCATCCAAAGTGTTACAAAG
miR-497 CCTGAGCTGAGTTCCTACAG GCGGCCGCGTGTGGGCAACAAAGACTCC
miR-195 GTGACACAAAAAACATCTGG GCGGCCGCATAAGCATCTGCCCCCAACC
miR-515-2 CGAGTAGCTGGGACTACAGG GCGGCCGCATACCAGCTACTCGGGAGGC
miR-144 ATTACGCCATCTCTGGCTTG GCGGCCGCACGTTTTCTGGGTATAGC
miR-34a ATGGAGTCTTGCTAGTTGCC GCGGCCGCTACGTGCAAACTTCTCCCAG
miR-449a TTGAAGTAATACATTTTGTG GCGGCCGCACTGTCTACTCCGAAAGAC
miR-146a GTAGAGACAAATTCTCCATG GCGGCCGCTTTCTCACAGGAACTCACAC
miR-655 AATCCGTGGAGGAAGCTTTC GCGGCCGCACAGCAAACACAGCAAAGC
miR-374 GTTCCTTTATTGGAAGTCTG GCGGCCGCAGGCACACAATAAATGTTTG
miR-524 AGTAGAGACAGGGTTTCACC GCGGCCGCGATAGAGAGACTCTGTCCGC
miR-520d CTGGTGTCTAACTCCTGAGA GCGGCCGCTGACCATTTGAAGCCAAGAG
miR-376a-1 CCTGAGTAGGTGCAAAGATG GCGGCCGCATTATGTGTGCACCAAGGGC
miR-23b AATTGTGTGTGTCGCATGGC GCGGCCGCGGTGCAGAACTTAGCCACTG
miR-23a GCCATGCAAGTTGCTGTAGC GCGGCCGCTTCCTGCTGAACTGAGCCAG
miR-199a-2 AGCGCATACCCAAACCTCCC GCGGCCGCGTCAAGAAGGCCTTACCCGC
miR-199b GGGGTTGGACACTAGGTAGG GCGGCCGCAGGTTTTGGGGTGAGGGAGG
miR-194-1 CTAATGGCATTATCTCACAG GCGGCCGCGATGACTTTAATCCTCTTCC
miR-202 CCTGCGCATAAATGTGGAGC GCGGCCGCTCCTCTCTGCATCCTGGGTC
miR-875 TATACCTCAGTTTTATCAGGTG GCGGCCGCGTGCATAGCTTCTGTAAAGG
miR-511-1 AATGGCCTCTAGTTGCATCC GCGGCCGCATAGATCACTTACCTGAGGG
Table 1: Primers used to clone microRNA precursors in this study (Continued)BMC Cancer 2009, 9:194 http://www.biomedcentral.com/1471-2407/9/194
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5'-GCGGCCGCGTCTTTTTGTCTTCTGCTGGA (3134–
3155) for Luc-CCND1-3'-UTR-2. Using the same strategy,
the amplified fragments were then cloned into the modi-
fied pGL3 where EcoR1 and Not1 sites were introduced so
that the UTR sequences were unidirectionally cloned
downstream the luciferase gene.
To delete miR-503 binding sites, we used a two step PCR
procedure. In the first PCR reaction, 2 sets of primers
CCND1-UTR-5.3 and CCND1-UTR-3.6 ACAAAAAACT-
GATCCTCCAAGCTGCGGCCTGTCCCCGGTGT;
CCND1-UTR-5.6 ACACCGGGGACAGGCCGCAGCTT-
GGAGGATCAGTTTTTTGT (complementary to CCND1-
UTR-3.6) and CCND1-UTR-Not1-3.4 were used to gener-
ate two overlapping PCR products where the miR-503
binding sites were deleted. In the second PCR reaction, we
used these two products as templates and primers
CCND1-UTR-5.3 and CCND1-UTR-Not1-3.4. Finally, the
PCR product was cloned into the pGL3 control vector as
above. All PCR products were verified by DNA sequenc-
ing.
Transfection
UMSCC10B or 293T cells were transfected using DNAfec-
tin reagent (Applied Biological Materials, British Colum-
bia, Canada) following the manufacturer's protocol. In
brief, cells were seeded at 40% confluence in a 12-well
plate and then transfected with 1 μg of plasmid DNA in
serum free medium the following day when the cells
reached about 70% confluence. The serum free media was
then replaced by normal growth medium after 16 h of
transfection.
Luciferase Assay
Luciferase assays were carried out in 293T cells to deter-
mine the effect of microRNAs on the activity of Luc-
CCND1-3'-UTR and the deletion mutant constructs. First,
cells were transfected with appropriate plasmids in 12-
well plates. Then, the cells were harvested and lysed for
luciferase assay 24 h after transfection. Luciferase activity
was determined by using a luciferase assay kit (Promega)
according to the manufacturer's protocol. Renilla luci-
ferase was used for normalization.
PCR/RT-PCR and real-time RT-PCR
PCR was performed to amplify pre-microRNA sequences
or the CCND1 3'-UTR sequence according to the standard
three-step procedure. Annealing temperature varied
depending on the primers used. For RT-PCR, we isolated
total RNA using Trizol reagent (Invitrogen) per the manu-
facturer protocol and used 1 μg RNA to synthesize cDNA
by SuperScriptase III (Invitrogen) with random primers.
Finally, the resultant cDNA was used in regular PCR or
real-time PCR reactions. To detect CCND1 mRNA levels,
we used the SYBR Green method with primers CCND1-
5.1 and CCND1-3.1.
CCND1-5.1 (sense) 5'-CAGGAGAGGAAAGCATGGAG
CCND1-3.1 (antisense) 5'-TCGGGTGAAATAATGGTGGT
To detect mature microRNA expression, we also used Tri-
zol reagent to isolate total RNA. Real-time PCR reactions
were performed in ABI 7500 HT thermal cycler according
to the manufacturer's protocol. Average levels of U6, 5s
RNA and β-actin were used as an internal control. The
fold-change between vector control and pre-microRNA
expression vector was calculated with the 2-ΔΔCt method
[27,28].
Cell growth inhibition assay
Cell growth assays were carried out by MTT [3-(4,5-
Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide]
as described previously [29]. In brief, cells were seeded in
96-well plates and incubated for various days before add-
ing MTT. Absorbance at 570 nm was measured in the
multi well plate reader (Thermo Scientific, Waltham,
MA). The relative values were calculated by expressing the
value at the first day as 1.
Western Blot
Cells were harvested and protein was extracted 2 days after
transfection as previously described [26]. Protein concen-
tration was determined by protein assay kit (Bio-Rad, Her-
cules, CA) and samples were separated in 12% SDS
polyacrylamide gels. Signals were revealed by a secondary
antibody labeled with IRDye 800CW and the signal inten-
sity was determined by Odyssey Infrared Imaging System
(LI-COR Biosciences).
Cell cycle analysis
Cell cycle analysis was performed using the standard pro-
pidium iodide method. In brief, UMSCC10B cells were
first transfected with either vector control or miR-503
expression vector. One day later, cells were then split and
grown for 24 h before harvesting for cell cycle analysis.
After fixing at 70% ethanol, the cells were stained with
propidium iodide along with RNase A. Finally, the cells
were analyzed by FACS Vantage flow cytometer (Becton-
Dickinson).
Statistical analysis
Statistical analysis of data was performed using the Stu-
dent's t test. Differences with p values less than 0.05 are
considered significant.
Results
To determine microRNA regulation of CCND1, we
searched for putative microRNAs that are able to targetBMC Cancer 2009, 9:194 http://www.biomedcentral.com/1471-2407/9/194
Page 6 of 13
(page number not for citation purposes)
CCND1 based on commonly cited prediction programs
such as miRanda [30]http://www.microrna.org and
TargetScan4 http://www.targetscan.org[31], PicTar http://
pictar.mdc-berlin.de/[32]. Apparently, different programs
may predict different microRNAs for a given coding gene.
We used miRanda as a primary source in this study. Based
on January 2008 Release version, we found a total of 58
microRNAs that potentially target CCND1 (Fig. 1). To
obtain a comprehensive picture of microRNA targeting for
CCND1, we made an attempt to test all 58 predicted
microRNAs.
We first cloned all of these microRNA precursors into
pCDH-CMV-MCS-EF1-copGFP (pCDH, System Bio-
sciences, Mountain View, CA) expression vector. As indi-
cated in Fig. 2A, the pre-microRNAs were expected to
express under control of the CMV promoter and eventu-
ally processed into mature microRNA by the cellular Dra-
sha and Dicer. Since this vector also carried green
fluorescent protein (GFP) tag, transfection rate can be eas-
ily monitored under a fluorescence microscope. We were
able to clone 51 of 58 microRNAs and then introduced
into 293T cells. Two days after transfection, RNA was iso-
lated, followed by real time RT-PCR analysis, which
revealed that 45 of them gave rise to a higher level of
mature microRNAs over the endogenous counterpart
(vector control) (Table 2). On average, the exogenous
microRNAs were up to a 100-fold higher than the endog-
enous microRNAs. The variations among different micro-
RNAs are also in part due to variations in the levels of
endogenous microRNAs. Therefore, the majority of these
microRNAs were highly expressed. Shown in Fig. 2B were
three microRNAs (miR-19a, miR-155 and miR-503) that
were ectopically expressed because these three microRNAs
were capable of suppressing Luc-CCND1-3'-UTR as dem-
onstrated in this study (Fig. 3).
Next, we cloned the CCND1 3'-UTR (NM_053056). As
indicated in Fig. 1, the CCND1 3'-UTR was about 3207 bp
in length with corresponding microRNA sites. Since this
fragment was relatively long, we divided it into two frag-
ments and separately cloned into pGL3 control vector,
generating Luc-CCND1-3'-UTR-1 and Luc-CCND1-3'-
UTR-2, which were overlapped by 58 bps. Having demon-
strated ectopic expression of these microRNAs and con-
struction of CCND1-3'-UTR luciferease reporters, we
introduced each of microRNAs listed in Table 2 into 293T
cells along with Luc-CCND1-3'-UTR-1 or Luc-CCND1-3'-
UTR-2. Luciferase assays indicated that although the
majority of microRNAs had no effect on its luciferase
The CCND1 3'-UTR with predicted microRNAs and luciferase constructs Figure 1
The CCND1 3'-UTR with predicted microRNAs and luciferase constructs. The CCND1 3'-UTR sequences (3207 
bp) is based on NM_053056. Three microRNAs identified to be positive to CCND1 in this study are indicated in green with 
relative positions. Those previously validated microRNAs are indicated in red. See Table 2 for detail positions.
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Table 2: Ectopic expression of microRNAs
Name Vector Vector IC miR miR IC V:DCT miR:DCT DDCT Fold change
19a 20.1 14.5 18.4 14.1 5.6 4.3 -1.2 2.4
491-3p 24.4 14.3 22.0 14.2 10.1 7.8 -2.4 5.1
296-3p 22.8 14.5 17.3 14.1 8.3 3.1 -5.2 36.1
532-3p 22.0 14.3 20.5 14.2 7.7 6.2 -1.5 2.9
188-3p 25.0 14.5 21.4 15.0 10.6 6.4 -4.2 17.9
579 27.3 14.5 23.3 14.1 12.9 9.2 -3.7 12.8
501-5p 23.0 14.5 19.2 14.1 8.5 5.1 -3.4 10.7
548c-3p 26.7 14.5 24.8 14.1 12.3 10.7 -1.6 3.1
219-1-3p 26.0 14.5 19.4 14.4 11.5 5.0 -6.5 92.9
519b-3p 28.6 14.3 22.9 14.2 14.3 8.7 -5.6 48.8
155 33.6 17.1 25.3 17.5 16.5 7.8 -8.7 415.9
519e 28.6 14.3 22.9 14.2 16.0 8.7 -7.3 155.0
139-3p 24.4 14.5 16.7 13.7 9.9 3.0 -6.9 118.5
203 26.2 14.5 15.3 14.1 11.7 1.2 -10.5 1436.2
142-3p 31.9 14.5 21.2 14.1 17.5 7.1 -10.3 1296.1
450b-5p 21.3 14.5 17.3 15.0 6.9 2.3 -4.5 23.2
193a-3p 24.9 14.5 19.0 14.4 10.4 4.7 -5.8 55.1
193b 24.0 14.3 20.3 14.1 9.7 6.2 -3.5 11.5
487b 26.3 14.3 17.6 14.1 12.1 3.4 -8.6 391.9
487a 28.3 14.5 19.0 15.0 13.9 4.1 -9.8 900.1
301a 25.1 14.5 22.0 15.0 10.6 7.1 -3.6 11.8
130a 25.0 14.3 16.1 14.1 10.8 2.0 -8.8 431.6
130b 20.4 14.5 17.4 14.3 5.9 3.2 -2.7 6.5
148a 21.1 14.7 16.6 14.6 6.4 2.0 -4.2 18.1
503 24.8 18.6 20.4 18.1 6.2 2.3 -3.9 14.5
152 24.2 14.5 15.5 14.1 9.7 1.4 -8.4 327.0
95 23.4 14.5 16.0 14.2 8.8 1.8 -7.0 128.3BMC Cancer 2009, 9:194 http://www.biomedcentral.com/1471-2407/9/194
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activity, a total of seven microRNAs, miR-19a, miR-153,
miR-503, miR-16, miR-34a, miR-195 and miR-424a sup-
pressed its luciferase activity by over 35% (Fig. 3). Among
those microRNAs, miR-16, miR-34a, miR-195 and miR-
424a were previously reported to suppress CCND1
[22,23,33]. On the other hand, miR-19a, miR-155, and
miR-503 have not been previously validated to target
CCND1. Therefore, we further characterized these three
microRNAs.
To further demonstrate that these microRNAs truly target
CCND1, we determined whether they are able to suppress
the endogenous CCND1 protein levels. Western blot anal-
ysis indicated that only miR-503 was able to suppress
CCND1 protein by over 40% (Fig. 4A and 4B) in
UMSCC10B cells in addition to its ability to suppress the
luciferase activity (Fig. 4D). Moreover, we examined the
CCND1 mRNA by real time PCR and found that only
miR-503 significantly reduced CCND1 mRNA (Fig. 4C).
These results suggest that miR-503 is a true microRNA for
CCND1 whereas it remains to be determined for their tar-
geting capability for the other two microRNAs.
To confirm that suppression of CCND1 is specific to miR-
503, we transfected the cells with anti-miR-503 along with
the reporter. In contrast to miR-503, anti-miR-503 caused
an increase in the luciferase activity compared to the
scrambled oligo (Fig. 5). To determine the importance of
two miR-503 binding sites, we deleted these two sites.
This deletion substantially impaired its suppression activ-
ity, suggesting that these two putative bindings are impor-
tant for miR-503-mediated suppression.
Given that CCND1 is a key protein regulating cell cycle,
we then determined whether suppression of CCND1 by
miR-503 has any effect on cell cycle. We found that miR-
550 21.7 14.5 16.1 14.4 7.2 1.7 -5.5 44.7
424 18.0 14.5 14.6 14.3 3.5 0.4 -3.1 8.5
16 16.8 14.3 15.6 14.2 2.5 1.4 -1.2 2.3
195 17.3 14.3 15.2 14.2 3.0 1.0 -2.1 4.2
144 30.1 14.5 24.2 14.2 15.6 10.0 -5.6 47.0
34a 27.4 15.5 19.0 14.6 11.9 4.4 -7.5 187.3
449a 25.2 14.3 15.6 14.2 10.9 1.4 -9.5 723.8
146a 34.6 14.5 25.6 14.5 20.1 11.1 -9.0 505.0
655 29.7 14.5 27.4 14.2 15.2 13.3 -1.9 3.8
374b 19.5 14.5 16.8 14.2 5.0 2.7 -2.3 5.1
520d-5p 31.8 14.5 25.8 13.7 17.3 12.1 -5.2 36.8
376c 29.3 14.5 18.7 14.1 14.9 4.6 -10.3 1296.1
23b 19.2 14.3 18.0 14.2 4.9 3.7 -1.2 2.2
199a-3p 27.6 14.5 17.5 14.1 13.1 3.4 -9.8 864.1
194 23.7 14.5 17.4 14.1 9.2 3.2 -6.0 62.4
202 31.2 14.5 18.4 13.7 16.7 4.7 -12.0 3959.2
875 23.4 14.5 15.7 13.6 8.8 2.1 -6.7 104.5
511 25.4 14.5 20.5 14.4 10.9 6.1 -4.9 29.1
Values are CTs except for fold change. IC, Internal controls, average of 5sRNA, U6 and β-actin; V, vector.
Table 2: Ectopic expression of microRNAs (Continued)BMC Cancer 2009, 9:194 http://www.biomedcentral.com/1471-2407/9/194
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Expression of exogenous microRNAs used for validation Figure 2
Expression of exogenous microRNAs used for valida-
tion. A, Schematic description of microRNA constructs. B, 
Expression of three microRNAs that were identified to be 
positive in this study. 293T cells were first transfected with 
indicated miRNAs and harvested 24 h after infection for 
extraction of RNA. The relative expression was determined 
by real-time PCR. Values are means of three transfection 
experiments.
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Validation of seven microRNAs capable of silencing CCND1 Figure 3
Validation of seven microRNAs capable of silencing 
CCND1. 293T cells were transfected with indicated Luc-
CCND1-3'-UTR along with corresponding miRNAs and har-
vested 24 h after transfection for luciferase assays as detailed 
in Materials and Methods. Values are means ± SE of three 
transfection experiments. **, p < 0.01.
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Suppression of the endogenous CCND1 by miR-503 Figure 4
Suppression of the endogenous CCND1 by miR-503. A and B, Western blot revealing reduction of CCND1 protein in 
miR-503 transfected UMSCC10B cells with quantitative measurement of three experiments (B). C, The same miR-503 trans-
fected UMSCC10B cells were subject to RNA extraction and real time PCR analysis. D. Luciferase assays in UMSCC10B cells. 
Values in B, C and D are means ± SE of three separate experiments. **, p < 0.01. Expt, Experiment.
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503 slightly increased G1 phase populations, but had
more profound effect on S phase populations (Fig. 6A).
Based on average of three separate experiments, suppres-
sion of S phase populations by miR-503 was statistically
significant (Fig. 6B). While the vector control revealed
25% of S phase populations, miR-503 cells revealed 20%
of S1 phase populations. This result is consistent with the
previous report that higher levels of CCND1 are associ-
ated with higher S phase populations in cancer cells [34].
Suppression of CCND1 by miR-503 is expected to reduce
cell growth. Therefore, we determined the effect of miR-
503 on cell growth by MTT assays. As shown in Fig. 6C,
miR-503 suppressed cell growth by about 31% compared
to vector control. On the other hand, anti-miR-503
enhanced cell growth by about 30%.
Discussion
Although there are numerous computer-aided algorithms
for prediction of microRNA targets, these predicted targets
remains to be experimentally validated and how many
microRNAs can actually target a single gene is not clear.
Our study suggests that the ratio of true target/predicted
target is relatively low in our system, and further suggest
the complexity of the microRNA/mRNA interactions.
There are numerous putative target genes for a given
microRNA. Similarly, for given protein coding gene, there
are often many putative microRNAs. Therefore, it would
be of merit to determine how many microRNAs can actu-
ally target a given gene. We chose CCND1 for two reasons.
First, it is a well known proto-oncogene that is implicated
in tumorigenesis. Second, CCND1 has a relative long UTR
so that a relative large number of putative microRNAs can
target it, which would allow us to make a good assessment
of microRNA targeting.
Among the 58 predicted microRNAs, we cloned 51 of
them. We found that 6 microRNA precursors did not
express sufficient amount of exogenous microRNAs.
Therefore, these microRNAs were excluded from valida-
tion. Among 45 microRNAs tested there were seven
microRNAs found to be positive based on luciferase
assays by arbitrary cutoff of 35% reduction. Thus, the pos-
itive ratio for tested microRNAs is about 16%. Although
some other microRNAs such as let-7b and miR-17 were
showed to be positive to CCND1 by other groups [21,24],
these microRNAs are not in the miRanda list and thus,
they were not tested in this study. As listed in Table 3, the
predicted microRNAs can be categorized into 4 groups.
The first group consists of 6 microRNAs which are over-
lapped in all three programs. Four of them have been val-
idated in the literature or in this study. The second group
consisting of microRNAs overlapped within miRanda and
PicTar; this group has an additional microRNA, i.e., miR-
195, which is also positive to CCND1. The third group of
microRNAs are overlapped within miRanda and
TargetScan4, consisting of 27 microRNAs. Among them,
we have validated miR-503 and miR-19a positive to
CCND1 by luciferase assays. The fourth group shares no
overlapped microRNAs with any of other programs. How-
ever, we still found one potential microRNA (miR-424)
for CCND1. Based on these comparisons, there appears to
be a tendency that the first group gives rise to the highest
possibility of positivity and the last group gives rise to the
lowest possibility of positivity. However, there is a possi-
bility that functional microRNA might be found in this
group, highlighting the necessity of experimental valida-
tion.
Given that CCND1 can be targeted by multiple microR-
NAs, it is our expectation that those microRNAs may
simultaneously target CCND1 in the same cell in concert
if they are present at the same time. In this case, it would
be interesting to determine whether they have a synergis-
tic suppressive effect on CCND1. In addition to the previ-
ously identified microRNAs such as miR-16 and miR-34a,
we found that microRNAs such as microRNA-503, which
have not been previously reported, can also target this
Effect of anti-miR-503 and miR-503 binding sites on the Luc- CCND1-3'-UTR activity Figure 5
Effect of anti-miR-503 and miR-503 binding sites on 
the Luc-CCND1-3'-UTR activity. 293T cells were trans-
fected with Luc-CCND1-3'-UTR-2 along with either scram-
bled oligo or anti-miR-503 and the harvested for luciferase 
assays 24 h after transfection. To determine the importance 
of miR-503 binding sites, the same cells were transfected 
with Luc-CCND1-3'-UTR-2-d, in which the miR-503 binding 
sites were deleted. Along with the reporter Luc-CCND1-3'-
UTR-2-d was either vector or miR-503. Values are means ± 
SE of three separate experiments. **, p < 0.01; n.s., not signif-
icant.
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Effect of miR-503 on cell cycle and cell growth Figure 6
Effect of miR-503 on cell cycle and cell growth. A, A representative cell cycle profile for vector control or miR-503 in 
UMSCC10B cells. B, Average of S phase populations. C, While miR-503 suppresses, anti-miR-503 increases cell growth. 
UMSCC10B cells were transfected with vector or miR-503, or scrambled oligo or anti-miR-503 and then grown for 4 days 
before MTT assays. Values in C are means ± SE of three separate experiments. **, p < 0.01; *, p < 0.05.
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gene. Four lines of evidence support that miR-503 specif-
ically targets CCND1. First, ectopic expression of miR-503
suppresses luciferase assays with Luc-CCND1-UTR. Sec-
ond, anti-miR-503 enhances the activity. Third, miR-503
does not only affect the luciferase activity, but also the
endogenous gene, as shown by western blot and real time
PCR. Forth, miR-503 suppresses tumor cell growth, con-
sistent with the notion that suppression of CCND1 would
inhibit cell growth. Although there is little information
available in the literature regarding function of miR-503,
our findings suggest that miR-503 is a putative tumor sup-
pressor.
The other two potential microRNAs (miR-19a and miR-
155) are also interesting because they show suppression
ability for the luciferase activity. However, they do not
seem to affect CCND1 protein or mRNA levels, which
could be due to the cell type specific effect or artifacts that
might be caused by luciferase assays. This remains to be
further determined.
In summary, we used a luciferase reporter system and sys-
tematically tested miRNAs that are predicted to target
CCND1 by a computer-aided prediction method. Our val-
idation results provide a relatively comprehensive picture
of miRNA/mRNA interactions. Thus, this information
may be valuable for future studies on the regulation of
this important gene.
Conclusion
This study suggests that miRNAs can interact with a target
mRNA at both conserved and non-conserved sites
although the conserved sites give rise to a higher positive
ratio than the latter. The overall ratio for positive target
sites among the predicted sites is relatively low. However,
since it is possible that miRNA/mRNA interactions may
depend on the cellular content, this ratio could be differ-
ent in a different cellular content. Therefore, our study
highlights the importance of experimental target valida-
tion.
Table 3: Comparison of predicted CCND1 microRNAs
Group 1 (M, T and P)
miR-15a miR-15b miR-16 miR-34a miR-23a miR-23b
Group 2 (M and P)
miR-15a miR-15b miR-16 miR-34a miR-195 miR-23a miR-23b
Group 3 (M and T)
miR-15a miR-15b miR-16 miR-34a miR-195 miR-424 miR-503
miR-19a miR-23a miR-23b miR-202 miR-497 miR-193a miR-193b
miR-449a miR-511 miR-494 miR-487a miR-655 miR-95 miR-374b
miR-494 miR-296-3p miR-548c-3p miR-548d miR-548c miR-520d-5p
Group 4 (M only)
miR-155 miR-491-3p miR-296-3p miR-532-3p miR-188-3p miR-579 miR-501-5p
miR-219-1-3p miR-340 miR-519b-3p miR-519e miR-515-3p miR-139-3p miR-203
miR-142-3p miR-450-5p miR-487b miR-301a miR-301b miR-130a miR-130b
miR-148a miR-152 miR-550 miR-545 miR-497 miR-144 miR-449a
miR-146a miR-655 miR-374b miR-524-5p miR-520d-5p miR-376c miR-199a-3p
miR-199b-3p miR-194 miR-202 miR-875-3p miR-511
*M, miRanda; T, TargetScan4; P, PicTar. microRNAs in bold only were validated in literature; those underlined were validated in both literature and 
in this study. Those in italicized were validated in this study only.BMC Cancer 2009, 9:194 http://www.biomedcentral.com/1471-2407/9/194
Page 13 of 13
(page number not for citation purposes)
Abbreviations
PCR: polymerase chain reaction; RT: reverse transcription;
UTR: untranslated region.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
QJ, MF and YM designed research, analyzed data and
wrote the paper; QJ performed experiments. All authors
read and approved the final manuscript.
Acknowledgements
This work was supported by grants CA102630 from NCI and McElroy 
Foundation. QJ was supported in part by China Scholarship Counsel of Edu-
cation Ministry, P.R. China.
References
1. Croce CM, Calin GA: miRNAs, cancer, and stem cell division.
Cell 2005, 122(1):6-7.
2. Chen CZ, Li L, Lodish HF, Bartel DP: MicroRNAs modulate
hematopoietic lineage differentiation.  Science 2004,
303(5654):83-86.
3. Hwang HW, Mendell JT: MicroRNAs in cell proliferation, cell
death, and tumorigenesis.  Br J Cancer 2006, 94(6):776-780.
4. Hammond SM: MicroRNAs as oncogenes.  Curr Opin Genet Dev
2006, 16(1):4-9.
5. Esquela-Kerscher A, Slack FJ: Oncomirs – microRNAs with a role
in cancer.  Nat Rev Cancer 2006, 6(4):259-269.
6. Gregory RI, Shiekhattar R: MicroRNA biogenesis and cancer.
Cancer Res 2005, 65(9):3509-3512.
7. Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S, Magri
E, Pedriali M, Fabbri M, Campiglio M, et al.:  MicroRNA gene
expression deregulation in human breast cancer.  Cancer Res
2005, 65(16):7065-7070.
8. Rosenfeld N, Aharonov R, Meiri E, Rosenwald S, Spector Y, Zepeniuk
M, Benjamin H, Shabes N, Tabak S, Levy A, et al.: MicroRNAs accu-
rately identify cancer tissue origin.  Nat Biotechnol 2008,
26(4):462-469.
9. Cimmino A, Calin GA, Fabbri M, Iorio MV, Ferracin M, Shimizu M,
Wojcik SE, Aqeilan RI, Zupo S, Dono M, et al.: miR-15 and miR-16
induce apoptosis by targeting BCL2.  Proc Natl Acad Sci USA
2005, 102(39):13944-13949.
10. O'Donnell KA, Wentzel EA, Zeller KI, Dang CV, Mendell JT: c-Myc-
regulated microRNAs modulate E2F1 expression.  Nature
2005, 435(7043):839-843.
11. Johnson SM, Grosshans H, Shingara J, Byrom M, Jarvis R, Cheng A,
Labourier E, Reinert KL, Brown D, Slack FJ: RAS is regulated by
the let-7 microRNA family.  Cell 2005, 120(5):635-647.
12. Takamizawa J, Konishi H, Yanagisawa K, Tomida S, Osada H, Endoh
H ,  H a r a n o  T ,  Y a t a b e  Y ,  N a g i n o  M ,  N i m u r a  Y ,  et al.:  Reduced
expression of the let-7 microRNAs in human lung cancers in
association with shortened postoperative survival.  Cancer Res
2004, 64(11):3753-3756.
13. Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E, Aldler
H, Rattan S, Keating M, Rai K, et al.: Frequent deletions and down-
regulation of micro- RNA genes miR15 and miR16 at 13q14
in chronic lymphocytic leukemia.  Proc Natl Acad Sci USA 2002,
99(24):15524-15529.
14. Eis PS, Tam W, Sun L, Chadburn A, Li Z, Gomez MF, Lund E, Dahlberg
JE: Accumulation of miR-155 and BIC RNA in human B cell
lymphomas.  Proc Natl Acad Sci USA 2005, 102(10):3627-3632.
15. Chan JA, Krichevsky AM, Kosik KS: MicroRNA-21 is an antiapop-
totic factor in human glioblastoma cells.  Cancer Res 2005,
65(14):6029-6033.
16. Brennecke J, Stark A, Russell RB, Cohen SM: Principles of micro-
RNA-target recognition.  PLoS Biol 2005, 3(3):e85.
17. Du T, Zamore PD: microPrimer: the biogenesis and function of
microRNA.  Development 2005, 132(21):4645-4652.
18. Lewis BP, Burge CB, Bartel DP: Conserved seed pairing, often
flanked by adenosines, indicates that thousands of human
genes are microRNA targets.  Cell 2005, 120(1):15-20.
19. Hobert O: Gene regulation by transcription factors and
microRNAs.  Science 2008, 319(5871):1785-1786.
20. Li Z, Wang C, Prendergast GC, Pestell RG: Cyclin D1 functions in
cell migration.  Cell Cycle 2006, 5(21):2440-2442.
21. Yu Z, Wang C, Wang M, Li Z, Casimiro MC, Liu M, Wu K, Whittle J,
Ju X, Hyslop T, et al.: A cyclin D1/microRNA 17/20 regulatory
feedback loop in control of breast cancer cell proliferation.  J
Cell Biol 2008, 182(3):509-517.
22. Liu Q, Fu H, Sun F, Zhang H, Tie Y, Zhu J, Xing R, Sun Z, Zheng X:
miR-16 family induces cell cycle arrest by regulating multiple
cell cycle genes.  Nucleic Acids Res 2008, 36(16):5391-5404.
23. Bonci D, Coppola V, Musumeci M, Addario A, Giuffrida R, Memeo L,
D'Urso L, Pagliuca A, Biffoni M, Labbaye C, et al.: The miR-15a-miR-
16-1 cluster controls prostate cancer by targeting multiple
oncogenic activities.  Nat Med 2008, 14(11):1271-1277.
24. Schultz J, Lorenz P, Gross G, Ibrahim S, Kunz M: MicroRNA let-7b
targets important cell cycle molecules in malignant
melanoma cells and interferes with anchorage-independent
growth.  Cell Res 2008, 18(5):549-557.
25. Krause CJ, Carey TE, Ott RW, Hurbis C, McClatchey KD, Regezi JA:
Human squamous cell carcinoma. Establishment and char-
acterization of new permanent cell lines.  Arch Otolaryngol 1981,
107(11):703-710.
26. Zhu S, Si ML, Wu H, Mo YY: MicroRNA-21 Targets the Tumor
Suppressor Gene Tropomyosin 1 (TPM1).  J Biol Chem 2007,
282(19):14328-14336.
27. Chen C, Ridzon DA, Broomer AJ, Zhou Z, Lee DH, Nguyen JT, Bar-
bisin M, Xu NL, Mahuvakar VR, Andersen MR, et al.: Real-time
quantification of microRNAs by stem-loop RT-PCR.  Nucleic
Acids Res 2005, 33(20):e179.
28. Lao K, Xu NL, Yeung V, Chen C, Livak KJ, Straus NA: Multiplexing
RT-PCR for the detection of multiple miRNA species in
small samples.  Biochem Biophys Res Commun 2006, 343(1):85-89.
29. Wu F, Chiocca S, Beck WT, Mo YY: Gam1-associated alterations
of drug responsiveness through activation of apoptosis.  Mol
Cancer Ther 2007, 6(6):1823-1830.
30. John B, Enright AJ, Aravin A, Tuschl T, Sander C, Marks DS: Human
MicroRNA targets.  PLoS Biol 2004, 2(11):e363.
31. Grimson A, Farh KK, Johnston WK, Garrett-Engele P, Lim LP, Bartel
DP: MicroRNA targeting specificity in mammals: determi-
nants beyond seed pairing.  Mol Cell 2007, 27(1):91-105.
32. Krek A, Grun D, Poy MN, Wolf R, Rosenberg L, Epstein EJ, MacMe-
namin P, da Piedade I, Gunsalus KC, Stoffel M, et al.: Combinatorial
microRNA target predictions.  Nat Genet 2005, 37(5):495-500.
33. Sun F, Fu H, Liu Q, Tie Y, Zhu J, Xing R, Sun Z, Zheng X: Downreg-
ulation of CCND1 and CDK6 by miR-34a induces cell cycle
arrest.  FEBS Lett 2008, 582(10):1564-1568.
34. Chen RW, Bemis LT, Amato CM, Myint H, Tran H, Birks DK, Eck-
hardt SG, Robinson WA: Truncation in CCND1 mRNA alters
miR-16-1 regulation in mantle cell lymphoma.  Blood 2008,
112(3):822-829.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2407/9/194/pre
pub